{"indexed":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T15:03:21Z","timestamp":1565449401536},"reference-count":41,"publisher":"Wiley","issue":"6","license":[{"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1","start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"delay-in-days":2693,"content-version":"tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"DOI":"10.1111\/j.1742-1241.2008.01768.x","type":"article-journal","created":{"date-parts":[[2008,4,17]],"date-time":"2008-04-17T14:31:38Z","timestamp":1208442698000},"page":"919-924","source":"Crossref","is-referenced-by-count":14,"title":"Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial","prefix":"10.1111","volume":"62","author":[{"given":"A. D.","family":"Anastasilakis","sequence":"first","affiliation":[]},{"given":"D. G.","family":"Goulis","sequence":"additional","affiliation":[]},{"given":"S. A.","family":"Polyzos","sequence":"additional","affiliation":[]},{"given":"S.","family":"Gerou","sequence":"additional","affiliation":[]},{"given":"G. N.","family":"Koukoulis","sequence":"additional","affiliation":[]},{"given":"Z.","family":"Efstathiadou","sequence":"additional","affiliation":[]},{"given":"M.","family":"Kita","sequence":"additional","affiliation":[]},{"given":"A.","family":"Avramidis","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2008,4,17]]},"reference":[{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1359\/JBMR.051014","article-title":"Effect of age-related chronic immobility on markers of bone turnover","volume":"21","author":"Chen","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2105\/AJPH.87.3.398","article-title":"The effect of hip fracture on mortality, hospitalization, and functional status: a prospective study","volume":"87","author":"Wolinsky","year":"1997","journal-title":"Am J Public Health"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00198-004-1681-7","article-title":"Fundamentals and pitfalls of bone densitometry using dual-energy X-ray absorptiometry (DXA)","volume":"15","author":"Watts","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","article-title":"Osteoporosis","volume":"367","author":"Sambrook","year":"2006","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","article-title":"Bisphosphonates: mechanisms of action","volume":"19","author":"Fleisch","year":"1998","journal-title":"Endocr Rev"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1359\/JBMR.050403","article-title":"Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover","volume":"20","author":"Nenonen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/PL00005830","article-title":"Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy","volume":"66","author":"Rosen","year":"2000","journal-title":"Calcif Tissue Int"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use","volume":"26","author":"Hodsman","year":"2005","journal-title":"Endocr Rev"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","article-title":"Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis","volume":"20","author":"Chen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/030079905X75096","article-title":"Development of an algorithm for using PINP to monitor treatment of patients with teriparatide","volume":"22","author":"Eastell","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/PL00004183","article-title":"Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy","volume":"11","author":"Fink","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00198-005-0035-4","article-title":"Changes in the RANK ligand\/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients","volume":"17","author":"Dobnig","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S8756-3282(00)00248-9","article-title":"Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy","volume":"26","author":"Christgau","year":"2000","journal-title":"Bone"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB16|cit16","first-page":"3537","article-title":"Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women","volume":"85","author":"Greenspan","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70\u2003mg compared with once-weekly risedronate 35\u2003mg in women with postmenopausal osteoporosis: a randomized double-blind study","volume":"20","author":"Rosen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1359\/jbmr.1999.14.5.792","article-title":"Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices","volume":"14","author":"Woitge","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00198-004-1819-7","article-title":"Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide","volume":"16","author":"Tahtela","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB22|cit22","first-page":"1796","article-title":"Comparison of total and bone specific alkaline phosphatase in skeletal and non-skeletal diseases","volume":"42","author":"Woitge","year":"1996","journal-title":"Clin Chem"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4158\/EP.12.1.48","article-title":"Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature","volume":"12","author":"Maalouf","year":"2006","journal-title":"Endocr Pract"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S8756-3282(00)00410-5","article-title":"Effect of high doses of oral risedronate (20\u2003mg\/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis","volume":"28","author":"Zegels","year":"2001","journal-title":"Bone"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1359\/JBMR.050714","article-title":"Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial","volume":"20","author":"Deal","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/jbmr.5650111005","article-title":"Effect of parathyroid hormone (hPTH[1-34]) infusion on serum 1,25-dihydroxyvitamin D and parathyroid hormone in normal women","volume":"11","author":"Kinyamu","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1210\/jcem-73-6-1345","article-title":"Response of the parathyroid gland to infusion of human parathyroid hormone-(1-34) [PTH-(1-34)]: demonstration of suppression of endogenous secretion using immunoradiometric intact PTH-(1-84) assay","volume":"73","author":"Cosman","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s001980200061","article-title":"Risedronate reduces the risk of first vertebral fracture in osteoporotic women","volume":"13","author":"Heaney","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s00198-002-1324-9","article-title":"Bone turnover and body weight relationships differ in normal-weight compared with heavier postmenopausal women","volume":"14","author":"Cifuentes","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/ajcn\/73.2.347","article-title":"Moderate energy restriction increases bone resorption in obese postmenopausal women","volume":"73","author":"Ricci","year":"2001","journal-title":"Am J Clin Nutr"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1373\/clinchem.2005.052761","article-title":"Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome","volume":"51","author":"Panidis","year":"2005","journal-title":"Clin Chem"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1210\/jc.2003-030501","article-title":"The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial","volume":"89","author":"Clowes","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s00198-003-1431-2","article-title":"Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database","volume":"14","author":"Papaioannou","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00198-006-0171-5","article-title":"Persistence with teriparatide in patients with osteoporosis: the UK experience","volume":"17","author":"Arden","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1185\/030079905X61875","article-title":"Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis","volume":"21","author":"Cramer","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.maturitas.2004.02.005","article-title":"Compliance with drug therapies for the treatment and prevention of osteoporosis","volume":"48","author":"McCombs","year":"2004","journal-title":"Maturitas"},{"key":"10.1111\/j.1742-1241.2008.01768.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00198-002-1370-3","article-title":"Tolerability and compliance with risedronate in clinical practice","volume":"14","author":"Hamilton","year":"2003","journal-title":"Osteoporos Int"}],"container-title":"International Journal of Clinical Practice","original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2008.01768.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T14:33:57Z","timestamp":1549809237000},"score":1.0,"subtitle":["Osteoporosis treatment effect on bone turnover markers"],"short-title":[],"issued":{"date-parts":[[2008,4,17]]},"references-count":41,"journal-issue":{"issue":"6"},"URL":"http:\/\/dx.doi.org\/10.1111\/j.1742-1241.2008.01768.x","relation":{"cites":[]},"ISSN":["1368-5031"],"subject":["General Medicine"]}